Swiss National Bank Sells 81,900 Shares of Becton Dickinson and Co (NYSE:BDX)

Swiss National Bank trimmed its position in shares of Becton Dickinson and Co (NYSE:BDX) by 7.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,046,573 shares of the medical instruments supplier’s stock after selling 81,900 shares during the quarter. Swiss National Bank’s holdings in Becton Dickinson and were worth $263,747,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the business. FMR LLC grew its stake in Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after buying an additional 842,590 shares during the last quarter. Ronna Sue Cohen lifted its position in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after purchasing an additional 416,459 shares in the last quarter. Fundsmith LLP lifted its position in shares of Becton Dickinson and by 0.9% during the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after purchasing an additional 35,453 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Becton Dickinson and by 0.7% during the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after purchasing an additional 23,645 shares in the last quarter. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Claire Fraser sold 1,429 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total value of $347,618.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Patrick Kaltenbach sold 275 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $235.00, for a total transaction of $64,625.00. Following the completion of the transaction, the executive vice president now owns 16,482 shares in the company, valued at $3,873,270. The disclosure for this sale can be found here. Insiders sold 24,529 shares of company stock worth $5,836,116 over the last 90 days. 0.12% of the stock is currently owned by company insiders.

BDX has been the topic of a number of research reports. Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 target price on the stock in a research report on Monday, May 13th. Piper Jaffray Companies reduced their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Morgan Stanley upped their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 16th. KeyCorp reiterated an “overweight” rating and set a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Finally, BMO Capital Markets reduced their target price on shares of Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $264.27.

NYSE BDX traded up $1.56 during trading hours on Friday, hitting $247.91. The company’s stock had a trading volume of 364,231 shares, compared to its average volume of 1,076,436. The stock has a fifty day moving average of $251.94 and a 200 day moving average of $244.27. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The firm has a market capitalization of $66.50 billion, a P/E ratio of 22.52, a PEG ratio of 1.84 and a beta of 1.11. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The business had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period in the prior year, the business posted $2.91 earnings per share. Becton Dickinson and’s revenue was up 1.7% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and Co will post 11.68 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.77 dividend. The ex-dividend date is Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.24%. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is total return in investing?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.